304 filings
EFFECT
NRBO
NeuroBo Pharmaceuticals Inc
24 Apr 24
Notice of effectiveness
12:15am
8-K
NRBO
NeuroBo Pharmaceuticals Inc
17 Apr 24
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating
8:30am
8-K
NRBO
NeuroBo Pharmaceuticals Inc
16 Apr 24
Other Events
4:30pm
S-3
NRBO
NeuroBo Pharmaceuticals Inc
Shelf registration
12 Apr 24
4:06pm
8-K
NRBO
NeuroBo Pharmaceuticals Inc
1 Apr 24
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
8:30am
8-K
ng7jm
28 Mar 24
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
8:01am
8-K
870 c60y504x
13 Mar 24
Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification
8:30am
8-K
51iysg40
4 Mar 24
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive
7:30am
8-K
9puspb4lnl
29 Feb 24
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
8:30am
8-K
0ery8zdx6bv
14 Feb 24
Other Events
8:52am
8-K
k1de7ie22
1 Feb 24
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
8:30am
8-K
2n9sy98eu64ftxgoszm
18 Jan 24
Full Data Readout Expected in the Second Half of 2024
8:30am
8-K
4lrzsphugs4e2
9 Jan 24
Other Events
8:45am
8-K
hoo80eypavth
28 Dec 23
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
9:00am
8-K
9mwrujjlnbet8ax428n
19 Dec 23
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
9:03am
8-K
x3x4qtvg
7 Dec 23
Regulation FD Disclosure
9:20am
8-K
7vczg
13 Nov 23
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:14pm
8-K
z4369tity
6 Nov 23
Departure of Directors or Certain Officers
8:20am